Abstract:Background & Aim: Although serum fibroblast growth factor 21 (FGF21) levels are associated with liver fat content in non-alcoholic liver fat disease (NAFLD), the precise nature of the association remains undetermined. Therefore, this study aimed to explore the potential dose–response relationship between FGF21 and liver fat content in NAFLD.Methods: For this exploratory randomized clinical trial, 220 NAFLD patients with central obesity were recruited via community-based screening and randomly assigned to either control, moderate or vigorous-moderate exercise groups for 12 months. After this exercise intervention, patients were followed-up for a further 12 months. Serum FGF21 levels were measured by ELISA. Intrahepatic triglyceride (IHTG) content was determined by proton magnetic resonance spectroscopy.Results: Of the 220 patients, 149 (67.7%) were female; mean age was 53.9 ± 7.1 years and mean BMI was 28.0 ± 2.9 kg/m2 for all patients. Baseline IHGT increased gradually (P = 0.029 for trend) according to baseline serum FGF21 quartiles 1, 2, 3 and 4 (212.3, 358.9, 538.7 and 793.5 pg/mL, respectively). On grouping the distribution of serum FGF21 level changes into quartiles at month 12, the relative IHTG loss increased as serum FGF21 levels were reduced (P = 0.004 for trend). A similar trend was observed at month 24 (P = 0.006 for trend). Multivariate linear regression analysis revealed that changes in serum FGF21 levels were independently associated with changes in IHTG at both month 12 [β (SE), 0.136 (0.118); P = 0.048] and month 24 [β (SE), 0.152 (0.139); P = 0.041]. Using restricted cubic spline regression, changes in serum FGF21 were strongly and positively associated with their corresponding relative IHTG loss at both month 12 and follow-up (Poverall = 0.017, Pnon-linear = 0.044 and Poverall = 0.020, Pnon-linear = 0.044, respectively, for dose–response).Conclusion: Serum FGF21 is strongly associated with liver fat content in a dose–response manner in centrally obese NAFLD patients. These findings support the use of serum FGF21 as a biomarker of liver fat content in NAFLD.

Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort.

Association Between Serum Free Fatty Acid Levels and Nonalcoholic Fatty Liver Disease: a Cross-Sectional Study

High Circulating Fibroblast Growth Factor-21 Levels as a Prognostic Marker in Fatty Pancreas Patients

Serum Fetuin A Level is Associated with Nonalcoholic Fatty Liver Disease in Chinese Population

High circulating fibroblast growth factor-21 levels as a screening marker in fatty pancreas patients

Associations of Serum Fibroblast Growth Factor 23 Levels with Obesity and Visceral Fat Accumulation

Relationship of postprandial fibroblast growth factor 21 with lipids, inflammation and metabolic dysfunction-associated fatty liver disease during oral fat tolerance test

High Serum Level of Fibroblast Growth Factor 21 is an Independent Predictor of Non-Alcoholic Fatty Liver Disease: A 3-Year Prospective Study in China

Proportion and clinical characteristics of metabolic-associated fatty liver disease and associated liver fibrosis in an urban Chinese population

The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients.

Circulating Fibroblast Growth Factor 21 Levels Are Closely Associated with Hepatic Fat Content: A Cross-Sectional Study

Association between Serum Ferritin Levels and Metabolic-associated Fatty Liver Disease in Adults: a Cross-sectional Study Based on the NHANES

Serum Fetuin-A Associated With Fatty Liver Index, Early Indicator Of Nonalcoholic Fatty Liver Disease A Strobe-Compliant Article

Dose–response relationship between serum fibroblast growth factor 21 and liver fat content in non-alcoholic fatty liver disease

Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently.

Fasting Serum Fructose is Associated with Metabolic Dysfunction-Associated Fatty Liver Disease: A Prospective Study

Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis

Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center

Contribution of fibroblast growth factor 23 to Framingham risk score for identifying subclinical atherosclerosis in Chinese men.

Cross-sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases

Insight to the Association among Fibroblast Growth Factor 21, Non-Alcoholic Fatty Liver Disease and Cardiovascular Outcomes: A Population-Based Study.